OBJECTIVES: To investigate the cost-effectiveness of dabigatran etexilate (dabigatran 150MG) in the Turkish health care setting. METHODS: A model was constructed to assess the cost-effectiveness of dabigatran versus warfarin. Direct cost of events (stroke, intracranial bleeding), physician visits, INR tests, medication and patients’ hospital transfers were considered. Outcome measure is defined as the total number of events prevented per year for a population of 1000 patients.  RESULTS: For a cohort of 1,000 patients, total cost of stroke in the warfarin arm was 468,672 TL/year and in the dabigatran arm 322,212 TL/year. Cost for intracranial bleeding events was 234,336 TL/year and 87,876 TL/year for warfarin and dabigatran, respectively. Total treatment cost in the warfarin arm was 1,395,693 TL/ year and in the dabigatran arm 1,654,728 TL/ year. The ICER for dabigatran was 25,903 TL/stroke prevented (Cost per stroke event is given as 29.292 TL in current the Turkish health care setting). CONCLUSIONS: A major limitation of this analysis is that it doesn’t account for disability costs, which are other major direct costs of the Turkish Social Security Institution. According to the World Health Organization, for counties where a willingness to pay threshold for ICERs doesn’t exist, such as in Turkey, ICERs remaining below 1-3 times of the GDP per capita per unit of health gain are deemed acceptable. Dabigatran can be considered cost-effective with an ICER per stroke avoided below the GDP per capita (31,280 TL estimated for 2012) when compared to current standard of care in Turkey, which is warfarin.